Position paper: the need for head-to-head studies comparing Avastin versus Lucentis.
Schmucker
Christine
C
German Cochrane Center, Institute of Medical Biometry and Medical Informatics, Department of Medical Biometry and Statistics, University Medical Center Freiburg, Stefan-Meier-Str. 26, 79104 Freiburg, Germany. schmucker@cochrane.de
Antes
Gerd
G
Lelgemann
Monika
M
D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000191:economics / Q000503:physiopathology; D017277:Drug Approval; D016527:Drug Costs; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy* / Q000191:economics / Q000503:physiopathology; D056687:Off-Label Use; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D000069579:Ranibizumab; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab